---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-24-018350"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2024-12-26T23:59:59+00:00"
generated_at: "2026-05-28T23:15:41.682282+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Precigen sells FCX-007 assets for $8.5M cash, exits Castle Creek collaboration

## Summary
- Asset Acquisition Agreement with Innovator 21 (Paragon affiliate) closed Dec 24, 2024 for $8.5M cash.
- Sold IP and royalty rights related to FCX-007, a clinical-stage candidate for Epidermolysis Bullosa.
- Precigen has no further rights or obligations to Castle Creek or retained product royalties.
- Proceeds to be used for working capital and general corporate purposes.

## SEC filing metadata
- accession: 0000950103-24-018350
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2024-12-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010324018350/0000950103-24-018350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010324018350/dp222589_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-24-018350
- JSON: https://secwatch.observer/filing/0000950103-24-018350.json
- Plain text: https://secwatch.observer/filing/0000950103-24-018350.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.